GB Sciences, Inc. (GBLX)
0.0004
0.00 (0.00%)
USD |
OTCM |
Jun 10, 16:00
GB Sciences Enterprise Value
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 2.154M |
| June 09, 2026 | 2.113M |
| June 08, 2026 | 2.154M |
| June 05, 2026 | 2.113M |
| June 04, 2026 | 2.154M |
| June 03, 2026 | 2.113M |
| June 02, 2026 | 2.113M |
| June 01, 2026 | 2.113M |
| May 29, 2026 | 2.113M |
| May 28, 2026 | 2.113M |
| May 27, 2026 | 2.113M |
| May 26, 2026 | 2.113M |
| May 22, 2026 | 2.113M |
| May 21, 2026 | 2.154M |
| May 20, 2026 | 2.154M |
| May 19, 2026 | 2.113M |
| May 18, 2026 | 2.113M |
| May 15, 2026 | 2.154M |
| May 14, 2026 | 2.113M |
| May 13, 2026 | 2.113M |
| May 12, 2026 | 2.113M |
| May 11, 2026 | 2.154M |
| May 08, 2026 | 2.073M |
| May 07, 2026 | 2.113M |
| May 06, 2026 | 2.113M |
| Date | Value |
|---|---|
| May 05, 2026 | 2.113M |
| May 04, 2026 | 2.073M |
| May 01, 2026 | 2.113M |
| April 30, 2026 | 2.113M |
| April 29, 2026 | 2.113M |
| April 28, 2026 | 2.113M |
| April 27, 2026 | 2.805M |
| April 24, 2026 | 2.113M |
| April 23, 2026 | 2.113M |
| April 22, 2026 | 2.113M |
| April 21, 2026 | 2.113M |
| April 20, 2026 | 2.113M |
| April 17, 2026 | 2.113M |
| April 16, 2026 | 2.113M |
| April 15, 2026 | 2.113M |
| April 14, 2026 | 2.113M |
| April 13, 2026 | 2.113M |
| April 10, 2026 | 2.113M |
| April 09, 2026 | 2.113M |
| April 08, 2026 | 2.113M |
| April 07, 2026 | 2.113M |
| April 06, 2026 | 2.113M |
| April 02, 2026 | 2.113M |
| April 01, 2026 | 2.113M |
| March 31, 2026 | 2.113M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 10.45M |
| CNBX Pharmaceuticals, Inc. | 1.322M |
| Arvinas, Inc. | -156.09M |
| Fulcrum Therapeutics, Inc. | -93.65M |
| Definium Therapeutics, Inc. | 2.085B |